5 unchanged sentences
4.1 Governance Agreement between the Company and Roivant Sciences Ltd., a Bermuda exempted company, dated January 11, 2015 (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K/A filed with the SEC on January 26, 2015)
−Removed: 10.1 Arbutus Biopharma Corporation 2016, Omnibus Share and Incentive Plan, as supplemented and amended (incorporated herein by reference to Exhibit 10.1 to the Registrants Current Report on Form 8-K filed with the SEC on June 1, 2020)
−Removed: 10.2 Arbutus Biopharma Corporation 2020 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.2 to the Registrants Current Report on Form 8-K filed with the SEC on June 1, 2020)
−Removed: 10.3*# Cross License Agreement, dated April 11, 2018, by and between the Company and Genevant Sciences Ltd.
−Removed: 10.4*# First Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd.
−Removed: And Genevant Sciences GmbH
−Removed: 10.5*# Second Amendment to Cross License Agreement, dated June 27, 2018, by and among the Company, Genevant Sciences Ltd.
−Removed: And Genevant Sciences GmbH
+Added: 10.1 Amendment No.
+Added: 2 to the Open Market Sale Agreement SM , dated August 7, 2020, by and between Arbutus Biopharma Corporation and Jefferies LLC (incorporated herein by reference to Exhibit 1.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on August 7, 2020.)
31.1* Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: 101 The following materials from Arbutus Biopharma Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in inline XBRL (eXtensible Business Reporting Language):
+Added: 101 The following materials from Arbutus Biopharma Corporation’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, formatted in inline XBRL (eXtensible Business Reporting Language):
(i) Condensed Consolidated Balance Sheets;
7 unchanged sentences
** Furnished herewith.
−Removed: # Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on August 7, 2020.
+Added: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on November 5, 2020.
ARBUTUS BIOPHARMA CORPORATION
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.